Hero H1

Heading 2

Heading 3

Heading 4

Heading 5

Heading 6

P tekst

P-Large Link

Text Link Button Text

Button text

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet.

Button Text

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet.

Button Text

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare.

Button Text

Ulrik Cordes

Founder, Chief Executive Officer

Business focused leader with 25 years’ experience in biotech and pharma.

Cecilia Hultén

Co-founder, Chief Financial Officer

Finance executive, entrepeneur and investor with extensive experience from capital markets and the startup scene.

Jørgen Dam

Co-founder, Chief Operating Officer

Jørgen has a profound experience in strategic and operational leadership within biotech and pharma.

January 18, 2022

Neo-antigen reactive T-cells affect clinical outcome in TIL therapy in melanoma

A broader T-cell repertoire is a great predicter for improved clinical outcome in TIL therapy in melanoma. Christina Heeke from our R&D team is co-first-author on this very interesting article investigating what exact epitopes that TIL therapy is actually reacting against.

Button Text

November 16, 2020

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ Tumor Infiltrating Lymphocytes in ovarian cancer, Friese, C. et al, Nature SR (2020)

Article investigating the effect of adding a αCTLA-4 during the initial TIL culture, which favors the expansion of CD8+ TILs from ovarian tumor fragments. Adding αCTLA-4 resulted in more potent anti-tumor TILs in comparison to standard TIL cultures, which may improve clinical outcome of TIL-based ACT in ovarian cancer.

Button Text

July 16, 2021

High-dose Tumor Infiltrating Lymphocyte product with improved phenotype and functionality, Friese, C et al. SITC 2021 conference (abstract # 175)

Poster illustrating that improving the initial TIL culture conditions results in a shortened expansion time while simultaneously improving the characteristics of the TIL product with a high dose of functional CD8+ T cells with potential anti-tumor activity

Button Text

Join our team in  the quest for curing cancer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Button Text

Cbio A/S – enabling cancer cure

Hero H1

Heading 2

Heading 3

Heading 4

Heading 5

Heading 6

Heading

Heading

Heading

Heading

Heading

Heading

Heading

Ulrik Cordes

Cecilia Hultén

Jørgen Dam

January 18, 2022

Neo-antigen reactive T-cells affect clinical outcome in TIL therapy in melanoma

November 16, 2020

CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ Tumor Infiltrating Lymphocytes in ovarian cancer, Friese, C. et al, Nature SR (2020)

July 16, 2021

High-dose Tumor Infiltrating Lymphocyte product with improved phenotype and functionality, Friese, C et al. SITC 2021 conference (abstract # 175)

Join our team in the quest for curing cancer

Join our team in  the quest for curing cancer